

FF

Principal Investigator/Program Director (Last, first, middle):

Schade, David S.

FORMTEXT

BIOGRAPHICAL SKETCH

Give the following information for the key personnel and consultants and collaborators.
Begin with the principal
investigator/program director. Photocopy this page for each person.

NAME

David S. Schade, M.D.

POSITION TITLE

Professor of Medicine

EDUCATION (Begin with baccalaureate or other initial professional education, such as
nursing, and include postdoctoral training.)

INSTITUTION AND LOCATION

DEGREE

YEAR

CONFERRED

FIELD OF STUDY

Davidson College, Davidson, NC
Washington Univ Med School, St. Louis, MO
UNM School of Med, Albuquerque, NM
UNM School of Med, Albuquerque, NM

B.A.

M.D.

Med Res

EndoFellow

1964

1968
1971-73
1973-75

Chemistry/Biology
Medicine
Medicine
Endocrinol/Metab

RESEARCH AND PROFESSIONAL EXPERIENCE: Concluding with present position, list, in chronological order, previous employment, experience, and honors. Key personnel include the principal investigator and any other individuals who participate in the scientific development or execution of the project. Key personnel typically will include all individuals with doctoral or other professional degrees, but in some projects will include individuals at the masters or baccalaureate level provided they contribute in a substantive way to the scientific development or execution of the project. Include present membership on any Federal Government public advisory committee. List, in chronological order, the titles, all authors, and complete references to all publications during the past three years and to representative earlier publications pertinent to this application. DO NOT EXCEED TWO PAGES.

Professional Experience/Employment

1960-1964 College Student, Davidson College, Davidson, NC
1960-1964 Medical Biological Technician NIMH, NIH, Bethesda, MD (summer)
1964-1968 Medical Student, Washington University, St. Louis, MO
1968-1969 Straight Medical Intern, Jewish Hospital, St. Louis, MO
1969-1971 Clinical Associate, Nat'l Heart and Lung Inst, NIH, Bethesda, MD
1971-1973 First & Second Year Medical Resident in Internal Med, Albuquerque, NM
1973-1974 NIH Training Grant - NIAMD; First Year Endocrinology Fellowship,
University of New Mexico School of Medicine, Albuquerque, NM
1974-1975 Special Postdoctoral NIH Fellowship, NIAMD: 2nd Year Endo
Fellowship, UNM School of Medicine, Albuquerque, NM
1975-1977 Research Associate, American Diabetes Association
1976-1980 Ass't Professor of Medicine, University of New Mexico School of
Medicine
1980-1984 Associate Prof of Medicine, University of New Mexico School of
Medicine
1985-1994 Principal Investigator, Diabetes Control and Complications Trial
1994-present Principal Investigator, Epidemiology of Diabetes Intervention &
Complications
1994-present Principal Investigator, Diabetes Prevention Program
1985-present Professor of Medicine, University of New Mexico School of Medicine
1988-present Director, General Clinical Research Center Core Laboratory
1995
5-1997 Chairman, Dean's Science Advisory Council

1996-present Vice Chairman for Research, Dept of Internal Medicine, UNM School of Medicine

1997-Director, Clinical Trials Center

1999-Chief, Division of Endocrinology, Dept of Internal Medicine

Honors and □□□□

awards

Undergraduate:

_____, American Soc of Clinical Pathology Meritorious Student Research Award, 1967; Lange Medical Award for Scholastic and Research Achievement, 1968; Board Certified, American Board of Internal Medicine, 1976; Recertified 1987; Endocrinology and Metabolism, 1975; NIH Research Career Development Award in Diabetes, 1977-82; Otto Brandman Award, Research & Teaching in Diabetes, 1982; Member, NIH Study Section (Surgery, Anesthesiology, Trauma), 1981-1985
Member, American Diabetes Association Research Review Committee, 1982-1984
Outstanding Investigator Award, Clinical Research Center, 1987
Charles Best Award for Diabetes Research, 1989
Ralph C. Williams Research Award, University of New Mexico School of Medicine, 1990

PHS 398 (Rev. 5/95) Page 8_ FF

Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b.

FF

Principal Investigator/Program Director (Last, first, middle): Schade, David S.

FORMTEXT

SELECTED PUBLICATIONS SINCE 1982 from a total of 282.

1. Schade DS, RP Eaton, WS Edwards, et al.: EE Bair, JT Love, RS Urenda, and JI Gaona, Jr.: A remotely programmable insulin delivery system. Successful short-term implantation in man. JAMA 247:1848-1853, 1982.
2. Schade DS, RP Eaton: Diabetic ketoacidosis: pathogenesis, prevention & therapy. Clin Endo Metab 12:321-38, 1983.
3. Schade DS, DA Drumm, WC Duckworth, et al: The etiology of incapacitating brittle diabetes. Diabetes Care 8:12-20, 1985.
4. Schade DS, DA Drumm, WC Duckworth. RP Eaton: Factitious brittle diabetes mellitus. Am J Med 78:777-84, 1985.
5. Schade DS, WC Duckworth: In search of the subcutaneous insulin resistance syndrome. N Engl J Med 315:147-153, 1986.
6. Schade DS: Brittle Diabetes - Strategies, Diagnosis and Treatment, Diabetes/Metabolism Reviews, 4:371-390, 1988.
7. Schade DS: Diabetic ketoacidosis. In: Current Therapy in Endocrinology and Metabolism. Bardin CW (Ed), Philadelphia, BC Decker, Inc., 1988, pp 305-308.
8. Schade DS: Brittle Diabetes - Strategies. Diagnosis and Treatment.

- Diabetes/Metab Rvw, Vol. 4, No. 4, 1988, pp. 371-390.
9. Schade DS: Surgery and Diabetes. In: Medical Clinics of North America, WB Saunders Publ, Rizza R, and DA Greene (Eds), Philadelphia, W. B. Saunders, 72:6, 1988, pp 1531-1543.
 10. Schade DS: Brittle diabetes: pathogenesis and therapy. In Ellenberg and Rifkin's Diabetes Mellitus: Theory and Practice Fourth Edition, Rifkin and Porte, eds. Elsevier Science Publishing Co., New York, 1990, pp 575-590.
 11. Krentz AJ, Boyle PJ, Macdonald LM, Schade DS: Octreotide: A long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. *Metabolism* 43(1):24-31, 1993.
 12. Schade DS: Subcutaneous octreotide infusion and brittle diabetes, Second opinion. *Clinical Diabetes*, 11:1, 1993.
 13. Burge MR, Hardy KJ, Schade DS: Short term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency. *J Clin Endocrinol and Metab* 76:1192-1198, 1993.
 14. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development & progression of long-term complications in IDDM. *NEJM* 329:977-986, 1993.
 15. Berelowitz M, Fischette C, Cefalu W, Schade DS, et al: Comparative efficacy of a once-daily controlled-release formulation of glipizide & immediate-release glipizide in patients with NIDDM. *Diabetes Care* 17(12):1460-4 1994.
 16. Schade DS, Burge MR: Brittle diabetes: Etiology and treatment in *Advances in Endocrinology and Metabolism*, Vol 6, eds. EL Mazzaferri, RS Bar & RA Kreisberg, Mosby-Year Book, Inc., Chicago, pp. 289-319, 1995.
 17. Waters D, Danska J, Hardy K, et al., incl Schade DS: Recombinant human growth hormone, insulin-like growth factor I, and combination therapy in AIDS-associated wasting. *Annals of Internal Medicine* 125(11):865-72, 1996.
 18. Burge MR, Waters DL, Holcombe JH, Schade DS. Prolonged efficacy of short acting insulin Lispro in combination with human Ultralente in insulin dependent diabetes mellitus. *J Clin Endocrinol Metab* 82:920-924, 1997.
 - Burge MR, Schade DS. Insulins. In: Hirsch IB, Riddle MC, eds. *Endocrinology and Metabolism Clinics of North America*. Philadelphia: W.B. Saunders, 1997:575-598.
 - Burge MR, Schmitz-Fiorentino K, Fischette C, Qualls CR, Schade DS. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. *JAMA* 279:137-143, 1998.
 - Rassam AG, Zeise TM, Burge MR, Schade DS. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. *Diabetes Care* 22:133-136, 1999.
 22. Schade DS, Boyle PJ, Burge MR, Johannes C, Valentine V: 101 tips for improving your blood sugar. NY, ADA, 1995, 2nd edition, 1999.
 - Schade DS, Boyle PJ, Burge MR, Valentine V, Robinson D: 101 tips for staying healthy with diabetes (and avoiding complications) New York, American Diabetes Association, 1996, 2nd edition, 1999.
 - Rassam AG, Zeise TM, Burge MR, Schade DS. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. *Diabetes Care* 22:133-136, 1999.
 - Burge MR, Sood V, Sobhy TA, Rassam AG, Schade DS. Sulphonylurea-induced

hypoglycaemia in type 2 diabetes mellitus. *Journal of Diabetes, Obesity and Metabolism*. 1:199-206, 1999.

Burge MR, Zeise T-M, Sobhy TA, Rassam AG, Schade DS: Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. *Diabetes Care* 1999;22:2037-43.

27. Lindeman RD, Schade D, LaRue A, Romero LJ, Liang HC, Baumgartner RN, Koehler KM, Garry PJ. Subclinical hypothyroidism in a biethnic, urban community. *Journal of the American Geriatrics Society* 47(6):703-709, 1999.

28. Burge MR, Kamin JR, Timm CT, Qualls CR, Schade DS. Low-dose epinephrine supports plasma glucose in fasted elderly patients with type 2 diabetes. *Metabolism* 49(2):195-202, 2000.

**APPEARS THIS WAY
ON ORIGINAL**